Click here to get full coverage on Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal - Yahoo Finance

Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal  Yahoo Finance

Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal - Yahoo Finance

Click here to get full coverage on Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more - CNBC

Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more  CNBC

Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more - CNBC

Click here to get full coverage on Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? - Zacks Investment Research

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock?  Zacks Investment Research

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? - Zacks Investment Research

Click here to get full coverage on MTSR news: Strategy's STRC preferred stock drops to a record low $89 - CoinDesk

MTSR news: Strategy's STRC preferred stock drops to a record low $89  CoinDesk

MTSR news: Strategy's STRC preferred stock drops to a record low $89 - CoinDesk

Click here to get full coverage on Metsera (MTSR): Assessing Valuation After This Year’s 167% Stock Surge - simplywall.st

Metsera (MTSR): Assessing Valuation After This Year’s 167% Stock Surge  simplywall.st

Metsera (MTSR): Assessing Valuation After This Year’s 167% Stock Surge - simplywall.st

Click here to get full coverage on Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part) (NYSE:PFE) - Seeking Alpha

Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part) (NYSE:PFE)  Seeking Alpha

Pfizer Gets Metsera: Why The $20.65 CVR Is Highly Likely To Pay Out (In Part) (NYSE:PFE) - Seeking Alpha

Click here to get full coverage on Metsera Inc (MTSR) Institutional Confidence - TradingKey

Metsera Inc (MTSR) Institutional Confidence  TradingKey

Metsera Inc (MTSR) Institutional Confidence - TradingKey

Click here to get full coverage on Metsera’s Stock Turbulence: Buy or Bail? - StocksToTrade

Metsera’s Stock Turbulence: Buy or Bail?  StocksToTrade

Metsera’s Stock Turbulence: Buy or Bail? - StocksToTrade

Click here to get full coverage on Why Metsera stock’s 20% surge signals a fierce Pfizer-Novo Nordisk bidding war - TradingView

Why Metsera stock’s 20% surge signals a fierce Pfizer-Novo Nordisk bidding war  TradingView

Why Metsera stock’s 20% surge signals a fierce Pfizer-Novo Nordisk bidding war - TradingView

Click here to get full coverage on Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera - CNBC

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera  CNBC

Pfizer boosts obesity drug prospects with $7.3 billion deal to buy Metsera - CNBC

Click here to get full coverage on Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera - Yahoo Finance

Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera  Yahoo Finance

Pfizer and Novo Nordisk Face Off in $10 Billion Battle for Metsera - Yahoo Finance

Click here to get full coverage on Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR) - Seeking Alpha

Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR)  Seeking Alpha

Metsera: An Emerging Contender In The GLP‑1 Arena (NASDAQ:MTSR) - Seeking Alpha

Click here to get full coverage on Institutional investors own a significant stake of 48% in Metsera, Inc. (NASDAQ:MTSR) - simplywall.st

Institutional investors own a significant stake of 48% in Metsera, Inc. (NASDAQ:MTSR)  simplywall.st

Institutional investors own a significant stake of 48% in Metsera, Inc. (NASDAQ:MTSR) - simplywall.st

Click here to get full coverage on MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18  renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera offers fewer shares, prices IPO above the range at $18 - renaissancecapital.com

Click here to get full coverage on Metsera (MTSR) Stock Price, News & Analysis - MarketBeat

Metsera (MTSR) Stock Price, News & Analysis  MarketBeat

Metsera (MTSR) Stock Price, News & Analysis - MarketBeat

Click here to get full coverage on Metsera Moves Fast in Crowded Obesity Market With IPO Plans - BioSpace

Metsera Moves Fast in Crowded Obesity Market With IPO Plans  BioSpace

Metsera Moves Fast in Crowded Obesity Market With IPO Plans - BioSpace

Click here to get full coverage on Metsera bid exit gives boost to Novo Nordisk shares - TradingView

Metsera bid exit gives boost to Novo Nordisk shares  TradingView

Metsera bid exit gives boost to Novo Nordisk shares - TradingView

Click here to get full coverage on Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox and more - CNBC

Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox and more  CNBC

Stocks making the biggest premarket moves: Metsera, Compass, Kenvue, Fox and more - CNBC

Click here to get full coverage on Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity. - renaissancecapital.com

Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity.  renaissancecapital.com

Metsera: MTSR IPO, Health Care - Phase 2 biotech developing nutrient stimulated hormone analog peptides for obesity. - renaissancecapital.com

Click here to get full coverage on Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more - CNBC

Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more  CNBC

Stocks making the biggest moves midday: Oracle, Apple, Metsera, Compass, Kenvue and more - CNBC

Click here to get full coverage on Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout - Yahoo Finance

Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout  Yahoo Finance

Pfizer doubles down on weight-loss treatments with up to $7.3 billion Metsera buyout - Yahoo Finance

Click here to get full coverage on Pfizer Completes Acquisition of Metsera - Business Wire

Pfizer Completes Acquisition of Metsera  Business Wire

Pfizer Completes Acquisition of Metsera - Business Wire

Click here to get full coverage on Novo Nordisk Shares Pop After Stepping Back From Metsera Chase - Yahoo Finance

Novo Nordisk Shares Pop After Stepping Back From Metsera Chase  Yahoo Finance

Novo Nordisk Shares Pop After Stepping Back From Metsera Chase - Yahoo Finance

Click here to get full coverage on Pfizer wins bidding war for Metsera with $10B offer - Yahoo Finance

Pfizer wins bidding war for Metsera with $10B offer  Yahoo Finance

Pfizer wins bidding war for Metsera with $10B offer - Yahoo Finance

Click here to get full coverage on Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News

Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s  MedCity News

Metsera’s IPO Raises $275M to Show How Its Obesity Drugs Can Top Current GLP-1s - MedCity News

Click here to get full coverage on MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO - renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO  renaissancecapital.com

MTSR IPO News - Obesity biotech Metsera files for a $100 million IPO - renaissancecapital.com

Click here to get full coverage on Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera - MedCity News

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera  MedCity News

Pfizer’s Sweeter $10B Offer Beats Novo Nordisk in Bidding War for Obesity Biotech Metsera - MedCity News

Click here to get full coverage on Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion - Investor's Business Daily

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion  Investor's Business Daily

Metsera Tumbles After The Pfizer-Novo Buyout Battle Ends At $10 Billion - Investor's Business Daily

Click here to get full coverage on This Hated Stock Suddenly Looks Like an Obesity Bargain - WSJ

This Hated Stock Suddenly Looks Like an Obesity Bargain  WSJ

This Hated Stock Suddenly Looks Like an Obesity Bargain - WSJ

Click here to get full coverage on Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio - Business Wire

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio  Business Wire

Pfizer to Acquire Metsera and its Next-Generation Obesity Portfolio - Business Wire

Click here to get full coverage on Why Metsera's Share Price Is Plummeting This Week - The Motley Fool

Why Metsera's Share Price Is Plummeting This Week  The Motley Fool

Why Metsera's Share Price Is Plummeting This Week - The Motley Fool

Click here to get full coverage on Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits - Reuters

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits  Reuters

Pfizer wins $10 billion bidding war for Metsera as Novo Nordisk exits - Reuters

Click here to get full coverage on 'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera - Investor's Business Daily

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera  Investor's Business Daily

'It's Getting Ugly,' Analyst Says As Pfizer Escalates Its Gloves-Off Fight For Metsera - Investor's Business Daily

Click here to get full coverage on Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal - Investopedia

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal  Investopedia

Pfizer Jumps Into Weight-Loss Drug Segment With $7.3 Billion Metsera Deal - Investopedia

Click here to get full coverage on Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway - Yahoo Finance

Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway  Yahoo Finance

Novo Nordisk Walks Away from $10 Billion Fight--And the Stock Rallies Anyway - Yahoo Finance

Click here to get full coverage on Pfizer Addresses Proposal for Metsera - Business Wire

Pfizer Addresses Proposal for Metsera  Business Wire

Pfizer Addresses Proposal for Metsera - Business Wire

Click here to get full coverage on Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News

Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal  MedCity News

Pfizer Lawsuits Allege Novo Nordisk’s Bid to Buy Obesity Biotech Metsera is Anticompetitive, Illegal - MedCity News

Click here to get full coverage on Pfizer licking its lips as Metsera presents positive weight loss data - The Pharma Letter

Pfizer licking its lips as Metsera presents positive weight loss data  The Pharma Letter

Pfizer licking its lips as Metsera presents positive weight loss data - The Pharma Letter

Click here to get full coverage on Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More - MedCity News

Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More  MedCity News

Pfizer’s $4.9B Metsera Acquisition Positions It to Become Major Player in Obesity Drugs & More - MedCity News

Click here to get full coverage on Metsera stock soars as Novo Nordisk, Pfizer sweeten bids in takeover battle - Investing.com

Metsera stock soars as Novo Nordisk, Pfizer sweeten bids in takeover battle  Investing.com

Metsera stock soars as Novo Nordisk, Pfizer sweeten bids in takeover battle - Investing.com

Click here to get full coverage on Metsera: Preview Of VESPER-1 Phase 2b Trial (MTSR) - Seeking Alpha

Metsera: Preview Of VESPER-1 Phase 2b Trial (MTSR)  Seeking Alpha

Metsera: Preview Of VESPER-1 Phase 2b Trial (MTSR) - Seeking Alpha

Click here to get full coverage on Pfizer rejects Novo Nordisk’s bid for Metsera as anti-competitive - Investing.com

Pfizer rejects Novo Nordisk’s bid for Metsera as anti-competitive  Investing.com

Pfizer rejects Novo Nordisk’s bid for Metsera as anti-competitive - Investing.com

Click here to get full coverage on Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med  MedCity News

Metsera’s Amylin Drug Looks Good in Phase 1, Shows Potential to be a Once-Monthly Obesity Med - MedCity News

Click here to get full coverage on SA Asks: Who's the next takeover target in the weight-loss drug space? - Seeking Alpha

SA Asks: Who's the next takeover target in the weight-loss drug space?  Seeking Alpha

SA Asks: Who's the next takeover target in the weight-loss drug space? - Seeking Alpha

Click here to get full coverage on Pfizer (PFE) is interested in future stock prices as it acquires MetSerra (MTSR), a company that dev.. - 매일경제

Pfizer (PFE) is interested in future stock prices as it acquires MetSerra (MTSR), a company that dev..  매일경제

Pfizer (PFE) is interested in future stock prices as it acquires MetSerra (MTSR), a company that dev.. - 매일경제

Click here to get full coverage on New robots help EOD teams do jobs safer, better, faster - jbsa.mil

New robots help EOD teams do jobs safer, better, faster  jbsa.mil

New robots help EOD teams do jobs safer, better, faster - jbsa.mil

Click here to get full coverage on New EOD robot arrival [Image 2 of 5] - DVIDS

New EOD robot arrival [Image 2 of 5]  DVIDS

New EOD robot arrival [Image 2 of 5] - DVIDS

Click here to get full coverage on Metsera, Inc. Common Stock (MTSR) Stock Forecast & Price Prediction 2026–2030 - CoinCodex

Metsera, Inc. Common Stock (MTSR) Stock Forecast & Price Prediction 2026–2030  CoinCodex

MTSR

Price Chart

Key Statistics

Technicals

About MTSR

Latest News

Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal - Yahoo Finance

Stocks making the biggest moves midday: Penn Entertainment, Metsera, Six Flags & more - CNBC

Time to Buy Pfizer (PFE) or Metsera (MTSR) Stock? - Zacks Investment Research

Advanced Charts

Top Gainers

Top Losers